Kjellen L, Lindahl U. Proteoglycans：structures and interactions[J] . Annu Rev Biochem, 1991, 60：443-475.
[2]
Iozzo RV. Matrix proteoglycans：from molecular design to cellular function[J] . Annu Rev Biochem, 1998, 67：609-652.
[3]
Capila I, Linhardt RJ. Heparin-protein interactions[J] . Angew Chem Int Ed Engl, 2002, 41：391-412.
[4]
Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications[J] . Int Rev Cell Mol Biol, 2009, 276：105-159.
[5]
Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis[J] . J Clin Invest, 2001, 108：341-347.
[6]
Gray E, Mulloy B, Barrowcliffe TW. Heparin and low molecular-weight heparin[J] . Thromb Haemost, 2008, 99：807-818.
[7]
Lindahl U. Heparan sulfate-protein interactions-a concept for drug design[J] . Thromb Haemost, 2007, 98：109-115.
[8]
Voldavsky I, Friedmann Y, Elkin M, et al. Cloning of heparanase：gene cloning, expression and function in tumor progression and metastasis[J] . Nat Med, 1999, 5：793.
[9]
Xu X, Ding J, Rao G, et al. Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endome-trium[J] . Hum Reprod, 2007, 22：927-937.
[10]
Fux L, Ilan N, Sanderson RD, et al. Heparanase：busy at the cell surface[J] . Trends Biochem Sci, 2009, 34：511-519.
[11]
Vreys V, David G. Mammalian heparanase：what is the message? [J] . Cell Mol Med, 2007, 11：427-452.
[12]
Vlodavsky I, Beckhove P, Lerner I, et al. Significance of heparanase in cancer and inflammation[J] . Cancer Microenviron, 2012, 5：115-132.
[13]
Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-mole-cular-weight heparin on cancer survival[J] . Thromb Haemost, 2007, 5：729-737.
[14]
Lerner I, Baraz L, Pikarsky E, et al. Function of heparanase in prostate tumorigenesis：potential for therapy[J] . Clin Cancer Res, 2008, 14：668-676.
[15]
Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer：correlation with tumor progression and patient surrival[J] . Neoplasia, 2006, 8：1055-1061.
[16]
Nobuhisia T, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with malignant potential in human colon cancer[J] . Cancer Res Clin Oncol, 2005, 131：229-237.
[17]
Raman K, Karuturi R, Swarup VP, et al. Discovery of novel sulfon-ated small molecules that inhibit vascular tube formation[J] . Bioorganic & Medicinal Chemistry Letters, 2012, 22：4467-4470.
[18]
Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis [J] . Int J Biochem Cell Biol, 2006, 38：2018-2039.
[19]
Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited： mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis[J] . Proc Natl Acad Sci USA, 2001, 98：3335-3357.
[20]
Dredge K, Hammond E, Handley P, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models[J] . British Journal of Cancer, 2011, 104：635-642.
[21]
Hammond E, Brandt R, Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcin-oma model[J] . PLoS One, 2012, 7：1-11.
[22]
Dredge K, Hammond E, Davis K, et al. The PG500 series：novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy[J] . Invest New Drugs, 2010, 28：276-283.
[23]
Levy-Adam F, Abboud-Jarrous G, Guerrini M, et al. Identification and characterization of heparin /heparan sulfate binding domains of the endoglycosidase heparanase[J] . J Biol Chem, 2005, 280：20457-20466.
[24]
Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes[J] . J Cell Sci, 2004, 117：2249-2258.
[25]
Marchetti D, Reiland J, Erwin B, et al. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues[J] . Int J Cancer, 2003, 104：167-174.
[26]
Miao HQ, Elkin M, Aingorn E, et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligo deoxynucleo tides[J] . Int J Cancer, 1999, 83：424-431.
[27]
Liu XY, Tang QS, Chen HC, et al. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity[J] . Int J Bio Sci, 2013, 9：564-577.
